Astellas US LLC et al v. Meitheal Pharmaceuticals, Inc.
| Gilead Sciences, Inc., Astellas US LLC and Astellas Pharma US, Inc. |
| Meitheal Pharmaceuticals, Inc. |
| 1:2020cv01182 |
| September 4, 2020 |
| US District Court for the District of Delaware |
| Colm F Connolly |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on October 14, 2020. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 11 ANSWER to #9 Answer to Complaint, Counterclaim by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc..(Oakes, Robert) |
| Filing 10 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Hong Kong King Friend Industrial Co. Ltd. for Meitheal Pharmaceuticals, Inc. filed by Meitheal Pharmaceuticals, Inc.. (Dorsney, Kenneth) |
| Filing 9 ANSWER to #1 Complaint, , COUNTERCLAIM against Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc. by Meitheal Pharmaceuticals, Inc..(Dorsney, Kenneth) |
| Filing 8 SUMMONS Returned Executed by Astellas US LLC, Astellas Pharma US, Inc., Gilead Sciences, Inc.. Meitheal Pharmaceuticals, Inc. served on 9/4/2020, answer due 9/25/2020. (Oakes, Robert) |
| Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) |
| Filing 7 Summonses Issued (please complete the top portion of the form and print out for use/service). (myr) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Astellas Pharma Inc., Corporate Parent Astellas US Holding, Inc. for Astellas Pharma US, Inc., Astellas US LLC filed by Astellas Pharma US, Inc., Astellas US LLC. (myr) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Gilead Sciences, Inc.. (myr) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,106,183 ;US RE 47,301 E ;US 8,524,883. (myr) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: August 18, 2020. Date of Expiration of Patent: February 2, 2027.Thirty Month Stay Deadline: 2/18/2023. (myr) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (myr) |
| Filing 1 COMPLAINT FOR PATENT INFRINGEMENT filed against Meitheal Pharmaceuticals, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number ADEDC-3178828.) - filed by Astellas US LLC, Astellas Pharma US, Inc., Gilead Sciences, Inc.. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D, #5 Civil Cover Sheet)(myr) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
